Key Financial Performance Q1 FY27
Revenue Performance:
- Revenue: ₹450 crores, representing 17% year-on-year growth
- Growth drivers: 10% patient volume growth, 11% test volume growth, with balance from richer product mix
- Sequential revenue growth: Approximately 6% from Q4 FY26
Channel-wise Performance:
- B2C business: 18% growth year-on-year
- B2B business: 15% growth year-on-year
- Rural centers: 36% revenue growth
Segment Performance:
- Specialty Diagnostics: 17% growth, contributes 40% of total revenue
- TruHealth: 22% growth, contributes 18% of total revenue
- Premium TruHealth packages: >50% growth
- Radiology integrated wellness packages: >40% growth
Profitability Metrics:
- EBITDA: ₹113 crores, 27% year-on-year growth
- EBITDA margin: 25.2%, expanded 210 basis points year-on-year
- PAT: ₹57 crores, 26% year-on-year growth
- PAT margin: 12.6%, expanded 90 basis points year-on-year
Operational Highlights
Network Expansion:
- Added 300 service centers in Q1 FY27
- Total service centers: More than 500 added in last 12 months
- Operating across 750 towns in India
- Center-to-laboratory ratio improved from 1:21 to 1:24 year-on-year
- Target: Improve ratio to 1:30 by year-end FY27
- Expansion plan: 400-500 centers in Tier-2 and Tier-3 towns in FY27
Volume Metrics:
- Patient volume growth: 10% year-on-year
- B2C patient volume: 13.5% growth
- B2B patient volume: 6% growth
- Test volume growth: 11% year-on-year
Geographic Performance:
- North India contribution: 18% of total revenue (up from single-digit pre-acquisition)
- North India growth: 19% year-on-year
- All regions delivered double-digit growth
Test Portfolio Development:
- Added 36 new tests during Q1 FY27
- Total specialty portfolio: More than 2,200 tests across gastroenterology, nephrology, neurology, oncology, and chronic diseases
- Previous year additions: 347 tests in FY26
- Quality metrics: 99% EQAS score, 99.99% report accuracy
Acquisition Integration Update
Core Diagnostics Integration:
- Acquisition completed: March 2025
- Acquisition valuation: <2x revenue
- Current effective multiple: Approximately 10x EBITDA based on FY27 expectations
- Integration status: Final leg of integration
- Current margin: High single-digit (approximately 8%)
- Target margin: 25% over 3-4 years from acquisition
Other Acquisitions:
- Scientific Pathology Agra: Completed towards end of Q1 FY27
- DAPIC Dehradun: Completed towards end of Q1 FY27
- Both performing ahead of revenue growth and EBITDA expectations
Strategic Priorities (Metropolis 3.0 Strategy)
1. Network Expansion: 400-500 centers in Tier-2 and Tier-3 towns in FY27
2. Specialty Diagnostics Strengthening: Target to increase contribution from 40% to 45%
3. TruHealth Portfolio Enhancement: Expanded to include basic radiology, vital checks, and consultations
4. Technology and AI Leverage: Continued investments in digital platforms and automation
5. Disciplined Inorganic Growth: Building acquisition funnel for strategically aligned assets
Guidance and Outlook
Revenue Guidance:
- Full-year FY27 revenue growth: 14%-15%
- Medium-term CAGR guidance: 14%-15%
- Volume component: 9%-10% from patient volume growth
- Mix component: 5%-6% from richer product mix
Margin Guidance:
- FY27 EBITDA margin expansion: 100-150 basis points
- Medium-term EBITDA margin target: 27%-28%
Capital Expenditure:
- FY26 CAPEX: ₹65 crores
- FY27 CAPEX: Expected to be similar to FY26 levels
Additional Business Updates
International Business:
- Market leaders in 2 out of 5 countries operated
- Top three player in all markets
- Healthy growth in both revenue and EBITDA
CGHS Business:
- Contribution: Approximately 1% of total revenue
- Minimal impact from recent CGHS price increases
Pricing Strategy:
- Last price increase: January 2025
- No price increases in Q1 FY27
- No immediate plans for near-term price increases
Laboratory Transformation:
- Standardizing testing platforms across network
- Vendor consolidation
- Increased automation
- Improving procurement efficiencies